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Coronary Artery Disease
Reduced MIs and Strokes With Intensive Statin Therapy
While some studies have shown significant benefit to aggressive lipid-loweringwith intensive statin therapy, other studies have not. Cannon and colleagues
performed ameta-analysis of the 4 large studies that compared intensivewithmoderate
lipid-lowering; TNT, IDEAL, A-to-Z, and PROVE IT–TIMI-22. These trials en-
rolled over 27,000 patients; intensive therapy subjects had amean low-density lipopro-
tein (LDL) of 75 mg/dl versus 101 mg/dl for moderate therapy. This LDL reduction
was associated with a significant 16% reduction for coronary death or myocardial
infarction (MI), and a 18% reduction in the risk of stroke. Cardiovascular death was
reduced by 12% which did not reach statistical significance; total mortality was not
affected.Thismeta-analysis of 4 large but heterogeneous studies suggests that LDL levels of
75mg/dl are superior to levels of 100mg/dl for preventing futureMIs and strokes, but has
limited benefit for reducing total mortality. See page 438. See figure.
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Cardiac
Resynchronization Therapy
Should All CRT Devices Have ICD Capability?
There has been conflicting evidence on the need for implantable cardioverter-defibrillator (ICD) capability in patients undergoing cardiac resynchronization
(biventricular pacing). Ypenburg and colleagues prospectively followed almost 200
patients with advanced heart failure, ejection fraction 35%, and a QRS duration
120 ms who received a combined cardiac resynchronization therapy (CRT)-ICD.
Patients were grouped as either primary or secondary prevention based on a history of
ventricular arrhythmias. During 1.5 years of follow-up, 21% of primary prevention
patients experienced an appropriate ICDtherapy,which is high, but significantly lower
than the 35% of secondary prevention patients. Both groups had similar clinical
improvements and time to first therapy; no significant predictors of the need for ICD
therapy were found. This study suggests that all patients who are candidates for CRT
should have a device with ICD capability because of the high rate of appropriate ICD
discharge in these patients. See page 464. See figure.
Hypertension
Genetic Variant in ANP Gene Linked to Ventricular Hypertrophy
Some individuals develop left ventricular hypertrophy (LVH) disproportionate totheir degree of hypertension. Atrial natriuretic peptide (ANP) prevents myocyte
hypertrophy in culture, and recent research has identified genetic variation in the
sequence for this gene. Rubattu and colleagues performed echocardiograms on 200
people with hypertension and then analyzed their deoxyribonucleic acid for variants of
the genes for ANP, brain natriuretic peptide, and the ANP receptor. Approximately
5% of subjects carried a polymorphism of the ANP promoter sequence which was
associated with increased left ventricular mass and posterior wall thickness. These
subjects also had lower serum levels of ANP providing a physiologic basis for the
association.This study demonstrates that a relatively common variant of theANPgene
is responsible for a significant downregulation of ANP gene transcription and is
associated with increased cardiac wall thickness in essential hypertension. See pages
499 and 506.
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Autonomic Function
Norepinephrine Transporter is a Potential Target for Treating Syncope
The etiology of neurally mediated syncope is poorly understood; the treatmentregimens also tend to be unsatisfactory. Schroeder and colleagues hypothesized
that norepinephrine transporter inhibitors (NETI) might be effective for neurally
mediated syncope by blocking pre-synaptic reuptake of norepinephrine thereby pre-
venting bradycardia and hypotension. Healthy volunteers underwent tilt-table testing
eitherwith orwithout aNETI.Themean tolerated tilt test durationwas increasedwith
NETI and subjects were nearly 5 times less likely to terminate the test early. This study
helps us to understand the etiology of neurally mediated syncope; preventive therapy
withNETI would require balancing the risk of increased heart rate and blood pressure
with the symptomatic benefits of less syncope. See page 516. See figure.
